ImmunologybioRxivPreprint
PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma
Olivia S. El Naggar, Binh N. Ha, Mahary Lalarizo Rakoto…·Gabriele Romano
This study shows that blocking PSGL-1 with BRAF/MEK inhibition improves durable tumor control in melanoma by reprogramming CD8+ T cells to a memory-like state.